Preimplantation genetic screening for aneuploidies in patients with advanced maternal age undergoing in vitro fertilisation

Submission date	Recruitment status No longer recruiting	Prospectively registered		
12/09/2005		Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
12/09/2005		[X] Results		
Last Edited	Condition category	[] Individual participant data		
20/10/2008	Pregnancy and Childbirth			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Sebastiaan Mastenbroek

Contact details

Center For Reproductive Medicine Academic Medical Center Meibergdreef 9 (A1-229) Amsterdam Netherlands 1105 AZ +31 (0)20 566 7524/3090 S.Mastenbroek@amc.uva.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

ZonMw: 945-03-013; NTR84

Study information

Scientific Title

Study objectives

To determine whether in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) combined with preimplantation genetic screening (PGS) in patients with advanced maternal age, i.e. women between 35 and 41 years of age, is a cost-effective alternative compared to IVF/ICSI without PGS.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from the local medical ethics committee

Study design

Randomised, active controlled, parallel group, double blinded, multicentre trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Screening

Participant information sheet

Health condition(s) or problem(s) studied

Subfertility, infertility

Interventions

Patients are allocated at random to one of two treatment arms:

- 1. IVF/ICSI with PGS (selection of embryos based on normal number of studied chromosomes), or
- 2. IVF/ICSI without PGS (selection of embryos based on morphology).

A maximum of two embryos will be transferred, according to the European Society of Human Reproduction and Embryology (ESHRE)-guidelines. In both treatment arms three treatment-cycles will be offered.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Ongoing pregnancy rate.

Secondary outcome measures

- 1. Time to pregnancy
- 2. Clinical pregnancy rate
- 3. Pregnancy outcome
- 4. Implantation rate

Overall study start date

01/05/2003

Completion date

01/05/2006

Eligibility

Key inclusion criteria

- 1. Women between 35 and 41 years of age
- 2. Undergoing IVF or ICSI

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

372

Key exclusion criteria

Does not comply with the above inclusion criteria

Date of first enrolment

01/05/2003

Date of final enrolment

01/05/2006

Locations

Countries of recruitment

Netherlands

Study participating centre Center For Reproductive Medicine Amsterdam Netherlands 1105 AZ

Sponsor information

Organisation

Academic Medical Center (AMC) (The Netherlands)

Sponsor details

Postbus 22660 Amsterdam Netherlands 1100 DD

Sponsor type

Hospital/treatment centre

Website

http://www.amc.uva.nl/

ROR

https://ror.org/03t4gr691

Funder(s)

Funder type

Research organisation

Funder Name

The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	05/07/2007		Yes	No